Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 19,2x - 21,2x | 20,2x |
| Selected Fwd EBIT Multiple | 11,2x - 12,4x | 11,8x |
| Fair Value | Mex$ 3.281 - Mex$ 3.701 | Mex$ 3.491 |
| Upside | -16,9% - -6,3% | -11,6% |
| Benchmarks | Ticker | Full Ticker |
| Amgen Inc. | AMGN | NasdaqGS:AMGN |
| CSL Limited | CMXH.F | OTCPK:CMXH.F |
| Vanda Pharmaceuticals Inc. | VNDA | NasdaqGM:VNDA |
| Biogen Inc. | BIIB | NasdaqGS:BIIB |
| Regeneron Pharmaceuticals, Inc. | REGN | NasdaqGS:REGN |
| AbbVie Inc. | ABBV * | BMV:ABBV* |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| AMGN | CMXH.F | VNDA | BIIB | REGN | ABBV * | ||
| NasdaqGS:AMGN | OTCPK:CMXH.F | NasdaqGM:VNDA | NasdaqGS:BIIB | NasdaqGS:REGN | BMV:ABBV* | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | -0.1% | 9.2% | NM- | -20.4% | 13.4% | 5.2% | |
| 3Y CAGR | 1.9% | 7.6% | NM- | -12.2% | -22.8% | -2.5% | |
| Latest Twelve Months | 0.2% | 2.7% | -191.4% | 23.4% | -2.1% | 3.8% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 33.9% | 28.1% | 2.7% | 29.7% | 40.8% | 35.2% | |
| Prior Fiscal Year | 34.3% | 25.7% | -7.2% | 19.1% | 32.3% | 32.5% | |
| Latest Fiscal Year | 28.9% | 26.3% | -20.5% | 24.0% | 29.2% | 32.5% | |
| Latest Twelve Months | 28.9% | 26.3% | -20.5% | 24.0% | 29.2% | 32.5% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 6.25x | 5.95x | -0.41x | 2.51x | 3.72x | 7.66x | |
| EV / LTM EBITDA | 13.8x | 19.0x | 2.5x | 8.1x | 11.4x | 16.2x | |
| EV / LTM EBIT | 21.6x | 22.6x | 2.0x | 10.5x | 12.8x | 23.6x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 2.0x | 12.8x | 22.6x | ||||
| Historical EV / LTM EBIT | 14.5x | 16.7x | 23.6x | ||||
| Selected EV / LTM EBIT | 19.2x | 20.2x | 21.2x | ||||
| (x) LTM EBIT | 18,332 | 18,332 | 18,332 | ||||
| (=) Implied Enterprise Value | 351,774 | 370,289 | 388,803 | ||||
| (-) Non-shareholder Claims * | (62,224) | (62,224) | (62,224) | ||||
| (=) Equity Value | 289,550 | 308,065 | 326,579 | ||||
| (/) Shares Outstanding | 1,769.0 | 1,769.0 | 1,769.0 | ||||
| Implied Value Range | 163.68 | 174.15 | 184.61 | ||||
| FX Rate: USD/MXN | 0.0 | 0.0 | 0.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 3,285.07 | 3,495.12 | 3,705.18 | 3,950.01 | |||
| Upside / (Downside) | -16.8% | -11.5% | -6.2% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | AMGN | CMXH.F | VNDA | BIIB | REGN | ABBV * | |
| Enterprise Value | 208,983 | 89,666 | (82) | 24,287 | 52,735 | 410,383 | |
| (+) Cash & Short Term Investments | 11,973 | 1,524 | 375 | 2,375 | 9,013 | 5,555 | |
| (+) Investments & Other | 4,770 | 0 | 0 | 424 | 9,060 | 279 | |
| (-) Debt | (60,879) | (11,964) | (12) | (6,717) | (2,939) | (68,019) | |
| (-) Other Liabilities | 0 | (1,987) | 0 | 0 | 0 | (39) | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 164,847 | 77,239 | 281 | 20,370 | 67,869 | 348,159 | |
| (/) Shares Outstanding | 537.2 | 484.2 | 58.3 | 146.4 | 107.0 | 1,769.0 | |
| Implied Stock Price | 306.86 | 159.51 | 4.81 | 139.16 | 634.14 | 196.81 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.05 | |
| Implied Stock Price (Trading Cur) | 306.86 | 159.51 | 4.81 | 139.16 | 634.14 | 3,950.01 | |
| Trading Currency | USD | USD | USD | USD | USD | MXN | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.05 | |